Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a… Grant US-11484535-B2 United States of America 01 Nov 2022
Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Grant US-11267818-B2 United States of America 08 Mar 2022
Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazol… Grant US-11214571-B2 United States of America 04 Jan 2022
Process for the preparation of pyrazolo[1,5-a]pyrimidines and salts thereof Grant US-11091486-B2 United States of America 17 Aug 2021
Macrocyclic compounds as ROS1 kinase inhibitors Grant US-10966985-B2 United States of America 06 Apr 2021
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same Grant US-10907215-B2 United States of America 02 Feb 2021
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]py… Grant US-10813936-B2 United States of America 27 Oct 2020
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]py… Grant US-10799505-B2 United States of America 13 Oct 2020
Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds Grant US-10774085-B2 United States of America 15 Sep 2020
Substituted pyrazolo[l,5-a]pyrimidine compounds as Trk kinase inhibitors Grant US-10758542-B2 United States of America 01 Sep 2020
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same Grant US-10724102-B2 United States of America 28 Jul 2020
Macrocylic compounds as ROS1 kinase inhibitors Grant US-10688100-B2 United States of America 23 Jun 2020
Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a… Grant US-10668072-B2 United States of America 02 Jun 2020
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same Grant US-10655186-B2 United States of America 19 May 2020
Macrocyclic compounds as TRK kinase inhibitors Grant US-10647730-B2 United States of America 12 May 2020
Method of treatment using substituted imidazo[1,2b]pyridazine compounds Grant US-10590139-B2 United States of America 17 Mar 2020
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same Grant US-10378068-B2 United States of America 13 Aug 2019
Point mutations in TRK inhibitor-resistant cancer and methods relating to the same Grant US-10370727-B2 United States of America 06 Aug 2019
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]py… Grant US-10285993-B2 United States of America 14 May 2019
Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors Grant US-10251889-B2 United States of America 09 Apr 2019
Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]py… Grant US-10172861-B2 United States of America 08 Jan 2019
Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A… Grant US-10137127-B2 United States of America 27 Nov 2018
Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds Grant US-10047097-B2 United States of America 14 Aug 2018